pancreatic cancer

OncoMed Pharmaceuticals has initiated a Phase Ib/II trial of anti-cancer stem cell therapeutic OMP-59R5 (Anti-Notch2/3) in small cell lung cancer (SCLC).

The enrolment of the first patient in the Phase Ib/II Pinnacle trial will trigger an $8m milestone payment from GSK, OncoMed’s strategic collaborator.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Pinnacle trial is designed to assess Anti-Notch2/3 in combination with cisplatin and etoposide in first-line extensive-stage SCLC patients.

Rocky Mountain Cancer Centers in Denver, Colorodo, medical oncologist, US Oncology Lung Committee developmental co-chair and trial principal investigator Dr Robert Jotte said Anti-Notch2/3 works by a novel anti-cancer stem cell mechanism to treat patients with small cell lung cancer.

"This disease is an aggressive form of cancer where patients are in need of new treatment options. We hope Pinnacle yields important data for these patients," Jotte said.

After a Phase Ib dose escalation and expansion phase, a randomised Phase II clinical trial will compare the efficacy of standard-of-care cisplatin and etoposide either with Anti-Notch2/3 or with placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Progression-free survival (PFS) in the Anti-Notch2/3 arm compared to placebo in patients who have a particular biomarker will be the primary endpoint of Phase II.

Overall survival, response rate and safety will be the secondary and exploratory endpoints.

OncoMed president and chief executive officer Paul Hastings said; "We have now initiated two proof-of-concept trials for our novel Anti-Notch2/3 antibody in the high un-met medical need indications of small cell lung cancer and pancreatic cancer."

In 2012, OncoMed initiated the antibody therapy in first-line pancreatic cancer investigating anti-notch efficacy and safety (Alpine) trial in first-line advanced pancreatic cancer patients.

The Anti-Notch2/3 (OMP-59R5) Phase 1b/2 Alpine trial has now been amended to include gemcitabine and abraxane chemotherapy.

Image: Histopathogic image of pancreatic adenocarcinoma arising in the pancreas head region. Photo: KGH.